Quest Diagnostics Incorporated (NYSE:DGX) agreed to acquire Select assets of PathAI Diagnostics on May 1, 2024. In connection with the acquisition, the PathAI Diagnostics state-of-the-art digitized laboratory in Memphis has been rebranded as AmeriPath and will act as the national AI and digital R&D and solutions center supporting Quest's specialty pathology businesses, AmeriPath and Dermpath Diagnostics. PathAI will continue to maintain a separate research laboratory at the same site in Memphis, Tennessee to support its biopharmaceutical clients.

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select assets of PathAI Diagnostics on June 11, 2024.